[1]王永斌,邓智勇,肖世闻,等.分化型甲状腺癌术后抑制状态下血清甲状腺球蛋白水平检测的临床诊断价值[J].现代检验医学杂志,2019,34(05):133-134.[doi:10.3969/j.issn.1671-7414.2019.05.033]
　WANG Yong-bin,DENG Zhi-yong,XIAO Shi-wen,et al.Clinical Value of Serumnon-Stimulated Thyroglobulin(nS-TG) in Differentiated Thyroid Cancer(DTC)Patients in after Thyroidectomy[J].Journal of Modern Laboratory Medicine,2019,34(05):133-134.[doi:10.3969/j.issn.1671-7414.2019.05.033]
点击复制

分化型甲状腺癌术后抑制状态下血清甲状腺球蛋白水平检测的临床诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
133-134
栏目:
检验与临床
出版日期:
2019-10-29

文章信息/Info

Title:
Clinical Value of Serumnon-Stimulated Thyroglobulin(nS-TG) in Differentiated Thyroid Cancer(DTC)Patients in after Thyroidectomy
文章编号:
1671-7414(2019)05-133-03
作者:
王永斌; 邓智勇; 肖世闻; 孟新尧
(云南省肿瘤医院核医学科,昆明 650118)
Author(s):
WANG Yong-bin; DENG Zhi-yong; XIAO Shi-wen; MENG Xin-yao
(Department of Nuclear,Yunnan Tumor Hospital,Kunming 650118,China)
关键词:
分化型甲状腺癌;  抑制状态;  甲状腺球蛋白;  抗甲状腺球蛋白抗体;  临床价值
分类号:
R736.1; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.05.033
文献标志码:
A
摘要:
目的 探讨分化型甲状腺癌( DTC)全切术后抑制状态时血清甲状腺球蛋白(TG)的临床价值。方法 回顾性分析云南省肿瘤医院2018年2～9月,75例接受甲状腺全切和131I清甲后的分化型甲状腺癌患者,口服甲状腺素片进行抑制治疗。用罗氏电化学发光e601检测血清TG,TSH和TG-Ab,安图A2000 plus检测FT4,联合甲状腺B超,CT检查。采用Mann-Whitney U检验比较转移组与未转移组TG,TSH,TG-Ab和FT4结果; 通过受试者工作特征曲线(ROC)分析血清TG在甲状腺癌术后,抑制治疗时复发转移的诊断性能。结果 分化型甲状腺癌术后,抑制状态,显像发现转移25例(33.3%),血清TG 49.02 ng/ml(95%CI:3.85～94.18 ng/ml); 未转移50例(66.7%),血清TG 0.84 ng/ml(95%CI:0.04～1.96 ng/ml),两组之间血清TG比较,差异有统计学意义(χ2=30.14,df=1,P<0.01)。通过ROC曲线分析,血清TG的ROC曲线下面积为0.88(95% CI:0.81～0.97,P<0.01),最佳切点值为1 ng/ml,此时诊断复发或转移的灵敏度为84.2%,特异度为88%。结论 抑制状态时血清TG水平变化有助于判断甲状腺癌术后复发或转移,甲状腺全切后抑制状态时血清TG水平为1 ng/ml可作为判断复发转移的最佳切点值,有较好的临床诊断价值。
Abstract:
Objective To evaluate the clinical value of serum non-stimulate thyroglobulin(nS-TG)in differentiated thyroid cancer(DTC)after thyroidectomy.Methods 75 patients with differentiated thyroid cancer(DTC)who had been treated with thyroidectomy between February to September 2018 in Yunnan Tumor Hospital.All of the patients had used thyroxine tablets.Used Roche 601 to assay the serum TG,TSH and TG-Ab,and Auto A2000plus to assay FT4,and connecting medical imaging inspect,and used ROC curve toanalyse the diagnosis characteristics of serum TG.Results The patients were divided into two groups through image:25(33.3%)transformed patients TG 49.02 ng/ml(95%CI:3.85～94.18)were more than the non-transform(66.7%)DTC patients which were 0.84 ng/ml(95%CI:0.04～2.11)(χ2=30.14,df=1,P<0.01).The ROC curve analysis showed the area underthe curve was 0.88(95% CI:0.81～0.97,P<0.01),there was difference in 1 ng/ml between transformed patients and the non-transform,which the sensitivitywas 84.2% and the specificity was 88%.Conclusion Theserum non-stimulate thyroglobulin(nS-TG)is useful to prognostic DTC after thyroidectomy,and the best cut off levels is 1ng/ml between transformed patients and the non-transform.

参考文献/References:

[1] 郑向前,侯秀坤,高明.2017年第二版NCCN甲状腺肿瘤指南解读[J].中国肿瘤临床,2018,45(1):14-17. ZHENG Xiangqian,HOU Xiukun,GAO Ming.Interpretation of the secondedition of the NCCN guidelines for thyroid cancer in 2017[J].Chinese Journalof Clinical Oncology,2018,45(1):14-17. [2] 魏伟军,沈晨天,宋红俊,等.超敏甲状腺球蛋白测定在分化型甲状腺癌随访中的应用[J].中华核医学与分子影像杂志,2016,36(5):474-478. WEI Weijun,SHEN Chentian,SONG Hongjun,et al.Application of ultrasensitive thyroglobulin assays in the follow-up of differentiated thyroid cercinoma[J].Chinese Journal of Nuclear Medicine and Molecular Imagine,2016,36(5):474-478. [3] XAVIER A C,MACIEL R M,VIEIRA J G,et al.Insights into the posttranslational structural heterogeneity of thyroglobulin and its role in the development,diagnosis,and management of benign and malignant thyroid diseases[J].ArchEndocrinal Metal,2016,60(1):66-75. [4] 赵靖,王荣福.血清Tg水平在分化型甲状腺癌诊疗进程中的临床价值[J].肿瘤学杂志,2016,22(11):880-884. ZHAO Jing,WANG Rongfu.The clinical value of serum thyroglobulin inthe managent of the patients with differentiated thyroid carcinoma[J].Journal of Chinese Oncology,2016,22(11):880-884. [5] 何凯骅,章斌,陈志强,等.血清sTg和TgAb水平监测甲状腺乳头状癌患者低剂量碘-131疗效的研究[J].现代检验医学杂志,2018,33(6):142-145. HE Kaihua,ZHANG Bin,CHEN Zhiqiang,et al.Value for clinical effect of low-dose 131I therapy in patients with papillary thyroid carcinomaby monitoring serum stimulated thyroglobulin and thyroglobulin antibody[J].JMod Lab Med,2018,33(6):142-145. [6] GIOVANELLA L,CLARK P M,CHIOVTO L,et al.Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer:a clinical position paper[J].Eur J Endocrinol,2014,171(2):33-46. [7] 中国抗癌协会甲状腺癌专业委员会.甲状腺癌血清标志物临床应用专家共识(2017版)[J].中国肿瘤临床,2018,45(1):7-13. China Anti-cancer Association of Thyroid Cancer Pro-fessional Committee of Chinese Anti-Cancer Association.Expert consensus for clinical application ofthyroid carcinomaserum marker in 2017[J].Chin J Clin Oncol,2018,45(1):7-13.

备注/Memo

备注/Memo:
作者简介:王永斌(1980-),男,本科,主管检验师,研究方向:免疫学检验,E-mail:13759115035@139.com。
更新日期/Last Update: 2019-10-20